# US 2019/0153477 A1 · Materials and methods for treatment of pain related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153477 A1
- Document ID: US20190153477A1
- Status: Published application
- Kind: A1
- Application number: 16/315,547
- Filed: 2017-07-06
- Published: 2019-05-23
- Earliest claimed: 2016-07-06
- Assignees: Crispr Therapeutics AG
- Applicants: CRISPR Therapeutics AG
- Inventors: Ante Sven Lundberg; Samarth Kulkarni; Lawrence Klein; Hari Kumar Padmanabhan
- Web page: https://patentgrep.com/patent/US20190153477A1

## CPC

- C12N 15/907: {in mammalian cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.

## Claims

### Claim 1

A method for editing a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene in a cell by genome editing comprising: introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene or SCN9A regulatory elements that results in one or more permanent insertions, deletions or mutations of at least one nucleotide within or near the SCN9A gene, thereby reducing or eliminating the expression or function of SCN9A gene products.

### Claim 2

An ex vivo method for treating a patient having an SCN9A related condition or disorder comprising:
(a) editing a patient specific induced pluripotent stem cell (iPSC) within or near a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene or other DNA sequences that encode regulatory elements of the SCN9A gene;
(b) differentiating the edited iPSC into a neuron of the peripheral nervous system; and
(c) administering said neuron of the peripheral nervous system to the patient.

### Claim 3 (depends on 2)

The method of claim 2, wherein the editing step comprises: introducing into the iPSC one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene or SCN9A regulatory elements that results in one or more permanent insertions, deletions or mutations of at least one nucleotide within or near the SCN9A gene, thereby reducing or eliminating the expression or function of SCN9A gene products.

### Claim 4

An ex vivo method for treating a patient having an SCN9A related condition or disorder comprising:
(a) editing a mesenchymal stem cell within or near a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene or other DNA sequences that encode regulatory elements of the SCN9A gene;
(b) differentiating the edited mesenchymal stem cell into a neuron of the peripheral nervous system; and
(c) administering the neuron of the peripheral nervous system to the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the editing step comprises: introducing into the mesenchymal stem cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene or SCN9A regulatory elements that results in one or more permanent insertions, deletions or mutations of at least one nucleotide within or near the SCN9A gene, thereby reducing or eliminating the expression or function of SCN9A gene products.

### Claim 6

An in vivo method for treating a patient with an SCN9A related disorder comprising: editing the Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene in a cell of the patient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the editing step comprises: introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene or SCN9A regulatory elements that results in one or more permanent insertions, deletions or mutations of at least one nucleotide within or near the SCN9A gene, thereby reducing or eliminating the expression or function of SCN9A gene products.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cell is a neuron of the peripheral nervous system.

### Claim 9 (depends on 8)

The method of claim 8, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is delivered to the neuron of the peripheral nervous system via direct intraganglionic or intraspinal injection, or intrathecal delivery.

### Claim 10

A method of altering the contiguous genomic sequence of an SCN9A gene in a cell comprising: contacting said cell with one or more deoxyribonucleic acid (DNA) endonuclease to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs).

### Claim 11 (depends on 10)

The method of claim 10, wherein the alteration of the contiguous genomic sequence occurs in one or more exons of the SCN9A gene.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is selected from any of those sequences in SEQ ID NOs: 1-620 and variants having at least 90% homology to any of those sequences disclosed in SEQ ID NOs: 1-620.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is one or more protein or polypeptide.

### Claim 14 (depends on 12)

The method of claim 12, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is one or more polynucleotide encoding the one or more DNA endonuclease.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is one or more ribonucleic acid (RNA) encoding the one or more DNA endonuclease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the one or more ribonucleic acid (RNA) is one or more chemically modified RNA.

### Claim 17 (depends on 16)

The method of claim 16, wherein the one or more ribonucleic acid (RNA) is chemically modified in the coding region.

### Claim 18 (depends on 14)

The method of claim 14, wherein the one or more polynucleotide or one or more ribonucleic acid (RNA) is codon optimized.

### Claim 19 (depends on 1)

The method of claim 1, wherein the method further comprises: introducing into the cell one or more gRNA or one or more sgRNA.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or more gRNA or one or more sgRNA comprises a spacer sequence that is complementary to a DNA sequence within or near the SCN9A gene.

### Claim 21 (depends on 19)

The method of claim 19, wherein said one or more gRNA or one or more sgRNA is chemically modified.

### Claim 22 (depends on 19)

The method of claim 19, wherein said one or more gRNA or one or more sgRNA is pre-complexed with the one or more deoxyribonucleic acid (DNA) endonuclease.

### Claim 23 (depends on 22)

The method of claim 22, wherein the pre-complexing involves a covalent attachment of said one or more gRNA or one or more sgRNA to the one or more deoxyribonucleic acid (DNA) endonuclease.

### Claim 24 (depends on 12)

The method of claim 12, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is formulated in a liposome or lipid nanoparticle.

### Claim 25 (depends on 19)

The method of claim 19, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is formulated in a liposome or lipid nanoparticle which also comprises the one or more gRNA or one or more sgRNA.

### Claim 26 (depends on 10)

The method of claim 10, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is encoded in an AAV vector particle.

### Claim 27 (depends on 19)

The method of claim 19, wherein the one or more gRNA or one or more sgRNA is encoded in an AAV vector particle.

### Claim 28 (depends on 19)

The method of claim 19, wherein the one or more deoxyribonucleic acid (DNA) endonuclease is encoded in an AAV vector particle, which also encodes the one or more gRNA or one or more sgRNA.

### Claim 29 (depends on 26)

The method of claim 26, wherein the AAV vector particle is selected from the group consisting of any of those disclosed in SEQ ID NOs: 4734-5302 and Table 2.

### Claim 30

A single-molecule guide RNA comprising: at least a spacer sequence that is an RNA sequence corresponding to any of SEQ ID NOs: 5305-125469.

### Claim 31 (depends on 30)

The single-molecule guide RNA of claim 30, wherein the single-molecule guide RNA further comprises a spacer extension region.

### Claim 32 (depends on 30)

The single-molecule guide RNA of claim 30, wherein the single-molecule guide RNA further comprises a tracrRNA extension region.

### Claim 33 (depends on 30)

The single-molecule guide RNA of claim 30, wherein the single-molecule guide RNA is chemically modified.

### Claim 34 (depends on 30)

The single-molecule guide RNA of claim 30 pre-complexed with a DNA endonuclease.

### Claim 35 (depends on 34)

The single-molecule guide RNA of claim 34, wherein the DNA endonuclease is a Cas9 or Cpf1 endonuclease.

### Claim 36 (depends on 35)

The single-molecule guide RNA of claim 35, wherein the Cas9 or Cpf1 endonuclease is selected from the group consisting of: S. pyogenes Cas9, S. aureus Cas9, N. meningitides Cas9, S. thermophilus CRISPR1 Cas9, S. thermophilus CRISPR 3 Cas9, T. denticola Cas9, L. bacterium ND2006 Cpf1 and Acidaminococcus sp. BV3L6 Cpf1, and variants having at least 90% homology to said endonucleases.

### Claim 37 (depends on 36)

The single-molecule guide RNA of claim 36, wherein the Cas9 or Cpf1 endonuclease comprises one or more nuclear localization signals (NLSs).

### Claim 38 (depends on 37)

The single-molecule guide RNA of claim 37, wherein at least one NLS is at or within 50 amino acids of the amino-terminus of the Cas9 or Cpf1 endonuclease and/or at least one NLS is at or within 50 amino acids of the carboxy-terminus of the Cas9 or Cpf1 endonuclease.

### Claim 39 (depends on 30)

A DNA encoding the single-molecule guide RNA of claim 30.
